Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Novartis's Entresto Clears NICE But It’s a Close Run Thing

Executive Summary

The innovative nature of Novartis's new chronic heart failure therapy Entresto counted towards NICE's appraisal committee clearing its use in Britain's National Health Service, despite a cost-effectiveness ratio that was close to the upper limit for gaining a positive recommendation.

Advertisement

Related Content

Novartis's Entresto Doesn't Impress In 1Q; Orphan Drug Fails In PhIII
IQWiG: Added Benefit Not Proven For Elocta, But Entresto Sails Through

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register